Necroptosis as a Novel Facet of Mitotic Catastrophe.
autophagy
doxorubicin treatment
mitotic catastrophe
necroptosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
25
01
2022
revised:
22
03
2022
accepted:
23
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Mitotic catastrophe is a defensive mechanism that promotes elimination of cells with aberrant mitosis by triggering the cell-death pathways and/or cellular senescence. Nowadays, it is known that apoptosis, autophagic cell death, and necrosis could be consequences of mitotic catastrophe. Here, we demonstrate the ability of a DNA-damaging agent, doxorubicin, at 600 nM concentration to stimulate mitotic catastrophe. We observe that the inhibition of caspase activity leads to accumulation of cells with mitotic catastrophe hallmarks in which RIP1-dependent necroptotic cell death is triggered. The suppression of autophagy by a chemical inhibitor or
Identifiants
pubmed: 35409093
pii: ijms23073733
doi: 10.3390/ijms23073733
pmc: PMC8998610
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Science Foundation
ID : 17-75-20102
Organisme : Russian Foundation for Basic Research
ID : 20-315-90018
Organisme : Russian Foundation for Basic Research
ID : 20-015-00157
Organisme : Swedish Cancer Society
ID : 190345
Organisme : Radium Hemmets Research Funds
ID : 181301
Références
Cell. 2014 Jul 17;158(2):464-464.e1
pubmed: 25036639
Oncogene. 2005 Jan 6;24(1):141-7
pubmed: 15531912
Oncogene. 2015 Nov 19;34(47):5796-806
pubmed: 25867066
J Pharmacol Sci. 2011;117(3):160-9
pubmed: 22027097
Cancer Biol Ther. 2013 Nov;14(11):999-1004
pubmed: 24025353
Oncogene. 2020 Jan;39(1):1-16
pubmed: 31462710
Biochim Biophys Acta. 2016 Apr;1865(2):228-36
pubmed: 26968619
Int J Mol Sci. 2020 Apr 16;21(8):
pubmed: 32316332
J Cell Sci. 2011 Sep 1;124(Pt 17):2951-63
pubmed: 21878502
Cell. 2012 Jan 20;148(1-2):213-27
pubmed: 22265413
Cell Death Differ. 2008 Jul;15(7):1153-62
pubmed: 18404154
Genes Dev. 2013 Aug 1;27(15):1640-9
pubmed: 23913919
Sci Rep. 2021 Dec 6;11(1):23490
pubmed: 34873207
J Biol Chem. 2011 Nov 11;286(45):38904-12
pubmed: 21930714
Oncogene. 2005 Jul 14;24(30):4765-77
pubmed: 15870702
Blood. 2012 Apr 12;119(15):3495-502
pubmed: 22343728
iScience. 2021 Mar 17;24(4):102320
pubmed: 33870135
Immunity. 2013 Sep 19;39(3):443-53
pubmed: 24012422
Science. 2015 Oct 16;350(6258):328-34
pubmed: 26405229
Mol Cell. 2019 Feb 7;73(3):413-428.e7
pubmed: 30598363
Drug Resist Updat. 2016 Jan;24:1-12
pubmed: 26830311
Elife. 2019 Jul 09;8:
pubmed: 31287416
Sci Rep. 2017 Nov 6;7(1):14571
pubmed: 29109414
Cancers (Basel). 2019 Dec 17;11(12):
pubmed: 31861153
Cell Rep. 2014 May 22;7(4):971-81
pubmed: 24813885
J Pharm Pharmacol. 2016 Feb;68(2):208-18
pubmed: 26730435
Autophagy. 2016 Nov;12(11):2085-2097
pubmed: 27629431
JCI Insight. 2020 Dec 3;5(23):
pubmed: 33108350
Cells. 2020 Aug 01;9(8):
pubmed: 32752206
Mol Cell. 2011 Aug 5;43(3):432-48
pubmed: 21737329
Cell Death Differ. 2017 Jan;24(1):83-97
pubmed: 27834956
Mol Cancer. 2020 Jan 22;19(1):12
pubmed: 31969156
Cancer Lett. 2016 Sep 28;380(1):31-8
pubmed: 27267809
J Hematol Oncol. 2019 Nov 26;12(1):123
pubmed: 31771633
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Nature. 2017 Oct 19;550(7676):402-406
pubmed: 28976970
FEBS J. 2015 Jan;282(1):19-31
pubmed: 25327580